...round. Investors included Samsung Venture Investment Corp., Shinhan Venture Investment, Smilegate Investment, Shinhan Investment Corp., Kolon...

...for investors’ decision was the quality partnering deal with Boehringer.” James Lee, Bridge In June, Kolon Life Science Inc....
...cell therapy was derived from kidney cells rather than cartilage cells as its label claimed. Kolon...

...at a $5.8 billion valuation. Bringing up the rear of the $1-$4.9 billion group was Kolon...
...FDA issues a complete response letter for HTX-011 to manage postoperative pain Kolon Life Science Inc. (KOSDAQ:102940) / Kolon...
...NASDAQ:INSY), Phoenix, Az. Iovance Biotherapeutics Inc. (NASDAQ:IOVA), San Carlos, Calif. Kolon Life Science Inc. (KOSDAQ:102940), Gwacheon, South Korea Kolon...

...expect FDA to make a decision within its standard review period. Korea revokes license for Kolon's...
...therapy South Korea's Ministry of Food and Drug Safety canceled the license for Invossa from Kolon Life Science Inc....
...derived from kidney cells, rather than cartilage cells as its label claimed. In April, partner Kolon...

...TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought. Kolon...
...and is down 42% since it announced the news in a regulatory filing Monday. Partner Kolon Life Science Inc....
...1 (TGFB1). Kolon TissueGene had thought the TGFB1-expressing cells used in the therapy were chondrocytes. Kolon...

...approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis (OA) of the knee. Partners Kolon Life Science Inc....
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...April deal, Mundipharma is marketing and distributing the product to general and semi-private hospitals, and Kolon...

...Md.) said Korea approved regenerative therapy Invossa-K Inj. to treat osteoarthritis of the knee. Partners Kolon Life Science Inc....
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...April deal, Mundipharma is marketing and distributing the product to general and semi-private hospitals, and Kolon...

...Korea) raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon...

...Eutilex raised W21 billion ($18.9 million) in a series A round from DS Asset Management, Kolon...

...and commercialize Invossa , which is in development to treat osteoarthritis (OA) of the knee. Kolon...
...human chondrocytes and allogeneic human chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon...
...Asian rights from TissueGene Inc. (Rockville, Md.) to develop and commercialize Invossa to regenerate cartilage. Kolon Life Science Inc....